//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
🌅 Check out the #SUNRISE phase 3 trial of tezepelumab in reducing OCS use in severe, OCS-dependent #asthma 🟥Efficacy and safety of tezepelumab vs placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent #asthma (SUNRISE) tinyurl.com/6h8xtr8w
6d
In this study, tezepelumab treatment led to greater reductions from baseline in daily oral corticosteroid dose than placebo at week 28 despite early study termination. No safety concerns were identifi...
www.thelancet.com
Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-b...
The Lancet Respiratory Medicine